| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9714258 | BRISTOL | Diaryl macrocycles as modulators of protein kinases |
Jan, 2035
(10 years from now) | |
| US10294242 | BRISTOL | Diaryl macrocycle polymorph |
Jul, 2036
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11452725 | BRISTOL | Chiral diaryl macrocycles and uses thereof |
Jul, 2036
(12 years from now) | |
Augtyro is owned by Bristol.
Augtyro contains Repotrectinib.
Augtyro has a total of 3 drug patents out of which 0 drug patents have expired.
Augtyro was authorised for market use on 15 November, 2023.
Augtyro is available in capsule;oral dosage forms.
Augtyro can be used as treatment of adult patients with locally advanced or metastatic ros1-positive non-small cell lung cancer (nsclc).
Drug patent challenges can be filed against Augtyro from 16 November, 2027.
The generics of Augtyro are possible to be released after 24 July, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-455) | Nov 15, 2030 |
| New Chemical Entity Exclusivity(NCE) | Nov 15, 2028 |
Drugs and Companies using REPOTRECTINIB ingredient
NCE-1 date: 16 November, 2027
Market Authorisation Date: 15 November, 2023
Treatment: Treatment of adult patients with locally advanced or metastatic ros1-positive non-small cell lung cancer (nsclc)
Dosage: CAPSULE;ORAL
AUGTYRO family patents
